Clinical Trials Logo

Clinical Trial Summary

Is acamprosate safe to use in individuals with liver disease.


Clinical Trial Description

Adult patients aged 21 or over with a diagnosis of alcohol-related liver disease and alcohol use disorder (AUD) and abstinent from alcohol for at least 2 weeks (but not more than 6 months) prior to initiating acamprosate treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04287920
Study type Interventional
Source Mayo Clinic
Contact
Status Completed
Phase Phase 2
Start date September 21, 2020
Completion date January 5, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04876443 - Impact of COVID-19 Outbreak on the Alcohol Consumption in Patients With Alcohol-related Liver Disease (ICoLD)
Recruiting NCT06409130 - Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease Phase 2
Completed NCT01812226 - Alcohol Biomarkers in Post-Liver Transplant Patients
Not yet recruiting NCT06305624 - Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease N/A
Active, not recruiting NCT06183710 - Contingency Management to Incentivise Treatment Adherence in Alcohol-related Liver Disease N/A
Recruiting NCT06403332 - Study of the Drivers of Late Diagnosis of Alcohol Related Diseases, Alone or in Combination With Metabolic Dysfunconal Associated Fatty Liver Disease, Implementation and Evaluation of Itnerventions to Reduce Its Burden. N/A
Not yet recruiting NCT05623150 - CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome
Not yet recruiting NCT06269510 - Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients N/A